Mark Walzer
- Developmental Neuroscience top 10%
-
- Neuroscience and Neuropharmacology Research 3
-
- Epilepsy research and treatment 3
- Fibromyalgia and Chronic Fatigue Syndrome Research 2
-
- Alzheimer's disease research and treatments 3
-
- Pharmacological Effects and Toxicity Studies 3
-
- Hormonal Regulation and Hypertension 3
-
- Stress Responses and Cortisol 2
-
- Glycosylation and Glycoproteins Research 2
- Co-authors
- William D. SniderFeng‐Quan ZhouIhor BekerskyDwain TolbertRobert A. BlumShoukat DedharJiang ZhouLois E. McCarthy
- Journals
- Journal of Psychopharmacology (2 papers)Experimental Neurology (1 paper)Molecular Genetics and Metabolism (1 paper)
- Partner nations
- United StatesNetherlandsGermany
In The Last Decade
Mark Walzer
21 papers receiving 424 citations
Peers
Comparison fields: 5 of 68
- Developmental Neuroscience 53
- Cellular and Molecular Neuroscience 178
- Neurology 83
- Neurology 38
- Psychiatry and Mental health 67
Countries citing papers authored by Mark Walzer
This map shows the geographic impact of Mark Walzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Walzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Walzer more than expected).
Fields of papers citing papers by Mark Walzer
This network shows the impact of papers produced by Mark Walzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Walzer. The network helps show where Mark Walzer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Walzer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 2 | |
| 5 | 2021 | 7 | |
| 6 | Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial | 2020 | 1 |
| 7 | 2020 | 7 | |
| 8 | 2020 | 14 | |
| 9 | 2019 | 13 | |
| 10 | 2018 | 1 | |
| 11 | 2017 | 5 | |
| 12 | First-in-human study of the 11β-hydroxysteroid dehydrogenase type 1 PET tracer [11C]AS2471907 | 2016 | 2 |
| 13 | 2012 | 63 | |
| 14 | 2011 | 11 | |
| 15 | 2006 | 81 | |
| 16 | 2004 | 91 | |
| 17 | 2004 | 30 | |
| 18 | 2003 | 1 | |
| 19 | 2002 | 31 | |
| 20 | 2002 | 39 |
About Mark Walzer
Mark Walzer is a scholar working on Behavioral Neuroscience, Developmental Neuroscience, Cellular and Molecular Neuroscience, Psychiatry and Mental health and Physiology, having authored 22 papers that have together received 432 indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (3 papers), Neuroscience and Neuropharmacology Research (3 papers), Epilepsy research and treatment (3 papers), Pharmacological Effects and Toxicity Studies (3 papers), Hormonal Regulation and Hypertension (3 papers), Stress Responses and Cortisol (2 papers), Glycosylation and Glycoproteins Research (2 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (2 papers). The work is most often cited by research in Developmental Neuroscience (53 citations), Cellular and Molecular Neuroscience (178 citations), Neurology (83 citations), Neurology (38 citations) and Psychiatry and Mental health (67 citations). Mark Walzer has collaborated with scholars based in United States, Netherlands and Germany. Frequent co-authors include William D. Snider, Feng‐Quan Zhou, Ihor Bekersky, Dwain Tolbert, Robert A. Blum, Shoukat Dedhar, Jiang Zhou, Lois E. McCarthy, Mark Frasier and Philipp J. Kahle. Their work appears in journals such as Journal of Psychopharmacology, Experimental Neurology, Molecular Genetics and Metabolism, Behavioural Brain Research and Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.